227 related articles for article (PubMed ID: 36521657)
1. Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Hong X; Zhang J; Zou J; Ouyang J; Xiao B; Wang P; Peng X
Cell Signal; 2023 Feb; 102():110560. PubMed ID: 36521657
[TBL] [Abstract][Full Text] [Related]
2. Molecular and clinical characterization of TMEM71 expression at the transcriptional level in glioma.
Wang KY; Huang RY; Tong XZ; Zhang KN; Liu YW; Zeng F; Hu HM; Jiang T
CNS Neurosci Ther; 2019 Sep; 25(9):965-975. PubMed ID: 31180187
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ
Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105
[TBL] [Abstract][Full Text] [Related]
4. Molecular Characterization of AEBP1 at Transcriptional Level in Glioma.
Wang K; Huang R; Tong X; Wang Z; Sun S; Wu C
Biomed Res Int; 2021; 2021():5579359. PubMed ID: 34373835
[TBL] [Abstract][Full Text] [Related]
5. The miR-26a/AP-2α/Nanog signaling axis mediates stem cell self-renewal and temozolomide resistance in glioma.
Huang W; Zhong Z; Luo C; Xiao Y; Li L; Zhang X; Yang L; Xiao K; Ning Y; Chen L; Liu Q; Hu X; Zhang J; Ding X; Xiang S
Theranostics; 2019; 9(19):5497-5516. PubMed ID: 31534499
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiling predicts response to temozolomide in malignant gliomas.
Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E; Tsumoto K
Int J Oncol; 2010 Jun; 36(6):1367-77. PubMed ID: 20428759
[TBL] [Abstract][Full Text] [Related]
7.
Chen Z; Cui S; Dai Y; Lu C; Zhang H; Zhao W; Yan H; Zhang Y
Oxid Med Cell Longev; 2022; 2022():7595230. PubMed ID: 36193074
[TBL] [Abstract][Full Text] [Related]
8. The pro-invasive factor COL6A2 serves as a novel prognostic marker of glioma.
Zhu J; Lin Q; Zheng H; Rao Y; Ji T
Front Oncol; 2022; 12():897042. PubMed ID: 36505882
[TBL] [Abstract][Full Text] [Related]
9. Exosomal circWDR62 promotes temozolomide resistance and malignant progression through regulation of the miR-370-3p/MGMT axis in glioma.
Geng X; Zhang Y; Lin X; Zeng Z; Hu J; Hao L; Xu J; Wang X; Wang H; Li Q
Cell Death Dis; 2022 Jul; 13(7):596. PubMed ID: 35817771
[TBL] [Abstract][Full Text] [Related]
10. Selenoprotein GPX1 is a prognostic and chemotherapy-related biomarker for brain lower grade glioma.
Chen X; Fu G; Li L; Zhao Q; Ke Z; Zhang R
J Trace Elem Med Biol; 2022 Dec; 74():127082. PubMed ID: 36155420
[TBL] [Abstract][Full Text] [Related]
11. Warburg effect-promoted exosomal circ_0072083 releasing up-regulates NANGO expression through multiple pathways and enhances temozolomide resistance in glioma.
Ding C; Yi X; Chen X; Wu Z; You H; Chen X; Zhang G; Sun Y; Bu X; Wu X; Lin Z; Gu J; Lin Y; Kang D
J Exp Clin Cancer Res; 2021 May; 40(1):164. PubMed ID: 33975615
[TBL] [Abstract][Full Text] [Related]
12. TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients.
Morelli MB; Nabissi M; Amantini C; Maggi F; Ricci-Vitiani L; Pallini R; Santoni G
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499683
[TBL] [Abstract][Full Text] [Related]
13. Resveratrol restores sensitivity of glioma cells to temozolamide through inhibiting the activation of Wnt signaling pathway.
Yang HC; Wang JY; Bu XY; Yang B; Wang BQ; Hu S; Yan ZY; Gao YS; Han SY; Qu MQ
J Cell Physiol; 2019 May; 234(5):6783-6800. PubMed ID: 30317578
[TBL] [Abstract][Full Text] [Related]
14. Regulation of temozolomide resistance in glioma cells via the RIP2/NF-κB/MGMT pathway.
Hu YH; Jiao BH; Wang CY; Wu JL
CNS Neurosci Ther; 2021 May; 27(5):552-563. PubMed ID: 33460245
[TBL] [Abstract][Full Text] [Related]
15. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
[TBL] [Abstract][Full Text] [Related]
16. Exosomal circ-HIPK3 Facilitates Tumor Progression and Temozolomide Resistance by Regulating miR-421/
Han C; Wang S; Wang H; Zhang J
Cancer Biother Radiopharm; 2021 Sep; 36(7):537-548. PubMed ID: 32644821
[No Abstract] [Full Text] [Related]
17.
Liang L; Yan B; Liu Y; Jiang S; He H; Huang J; Liu W; Xie L
Dis Markers; 2022; 2022():4534080. PubMed ID: 35401877
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of circHIPK3 Facilitates Temozolomide Sensitivity in Glioma by Regulating Cellular Behaviors Through miR-524-5p/KIF2A-Mediated PI3K/AKT Pathway.
Yin H; Cui X
Cancer Biother Radiopharm; 2021 Sep; 36(7):556-567. PubMed ID: 32833501
[No Abstract] [Full Text] [Related]
19. CD90
Xue BZ; Xiang W; Zhang Q; Wang HF; Zhou YJ; Tian H; Abdelmaksou A; Xue J; Sun MX; Yi DY; Xiong NX; Jiang XB; Zhao HY; Fu P
Stem Cell Res Ther; 2021 Jul; 12(1):394. PubMed ID: 34256854
[TBL] [Abstract][Full Text] [Related]
20. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]